G蛋白質複合受體：將會開啟新時代嗎

G蛋白質複合受體：將會開啟新時代嗎 是由出版商Insight Pharma Reports在2008年10月所出版的。 這份英文市場調查報告書包含192 pages 價格從美金3195起跳。

簡介

目錄

Abstract

Current advances in functional screening methodologies, medicinal chemistry, and structure-based drug design have generated large increases in the number and diversity of GPCR drug targets. Furthermore, basic research advances have opened the way for still further exploitation of this target class. This report:

• Explores current and likely consequences of recent advances concerning GPCR x-ray structures, allosteric interactions, multimerization, and functional selectivity;
• Extensively tabulates marketed drugs and compounds in development arranged by receptor type and subtype;
• Presents in-depth interviews with recognized experts in the field.

G protein-coupled receptors (GPCRs) are popular drug targets, accounting for about one-third of approved drugs and many hundreds of drugs currently in development. Yet one can easily argue that the pharmacologic potential of GPCRs is far from exhausted. Currently approved drugs address only a few GPCRs. Technologic and scientific advances have resulted in R&D pipelines that target a great many more GPCRs than are represented among currently marketed products. In this report, we examine newer technologies used in GPCR pharmacology.

Furthermore, the evolution of GPCR pharmacology is far from over. Basic researchers have made a number of exciting and relevant discoveries in the past decade, and these have already begun to make important contributions to drug discovery. GPCRs: Dawn of a New Era? examines the current state of basic research, featuring key developments with the potential to favorably impact future drug discovery.

We consider the exciting area of allosteric modulation, which has already yielded two marketed drugs and promises many more, some with capabilities heretofore inaccessible. We also examine two other areas in basic research that promise to have significant impact on the field: functional selectivity and the role of homo- and heterodimers in GPCR function. Another basic research advance, described herein, has, arguably, the greatest potential for advancing GPCR pharmacology. Until this year, drug discovery scientists had available to them only a single high-resolution x-ray crystallographic structure of a GPCR. That was for rhodopsin, which is atypical from the drug discovery perspective. Two relevant structures have become available, thus energizing the GPCR structure-based drug design community.

GPCRs: Dawn of a New Era? then examines trends in applied GPCR research before turning to a thorough presentation and analysis of marketed GPCR-based drugs and of compounds currently in development or registration. We consider all GPCR types and subtypes that are the subject of approved drugs or pipeline candidates. The report spotlights numerous small pharmaceutical companies, which tend to push the limits of GPCR pharmacology by attacking more targets and by attempting to apply cutting-edge concepts derived from basic research. In addition, we present a compendium of views on a variety of relevant findings and issues in the field based on our extensive discussions with GPCR experts.

Table of Contents

Chapter 1

• INTRODUCTION: THE UNTAPPED PHARMACOLOGIC POTENTIAL OF GPCRS
• 1.1. Research Advances Stimulating GPCR-Based Drug Discovery
• 1.2. Goals and Organization of Report

Chapter 2

• SCIENTIFIC BACKGROUND AND TECHNOLOGIES
• 2.1. Nature of GPCRs
• GPCRs as Drug Targets
• GPCR Classification
• 2.2. Compound Selection
• Functional Assays for GPCR Signaling
  • *Calcium Assays
  • *Cellular Dielectric Spectroscopy
  • *Beta-Arrestin Assays
• Structure-Based Drug Discovery

Chapter 3

• GPCR PHARMACOLOGY: KEY ADVANCES IN BASIC RESEARCH
• 3.1. Significance of GPCR Structures
• X-Ray Crystallographic Structure of the Beta2-Adrenergic Receptor・ ・ ・ Solved
• Implications for Structure-Based Drug Design for GPCRs
• 3.2. Deorphanization
• 3.3. Allosteric Modulators
• 3.4. Dimers and Oligomers
• 3.5. Functional Selectivity

Chapter 4

• APPLIED RESEARCH
• 4.1. Small Companies Push the Limits of GPCR Pharmacology
• 7TM Pharma
• Acadia Pharmaceuticals
• Actelion
• AcurePharma
• Addex Pharmaceuticals
• Adenosine Therapeutics (Acquired by Clinical Data)
• Arena Pharmaceuticals
• Cara Therapeutics
• Dimerix Bioscience
• EPIX Pharmaceuticals
• Trevena
• 4.2. The GPCR Pipeline
• Serotonin Receptors
  • *5-HT1 Receptor
  • *5-HT2 Receptor
  • *5-HT4 to 5-HT7 Receptors
• Adenosine Receptors
  • *A1 Receptor
  • *A2 and A3 Receptors
• Adrenergic Receptors
  • *Alpha Adrenergic Receptor
  • *Beta Adrenergic Receptor
• Angiotensin II Receptor
• Arginine Vasopressin Receptor
• Bradykinin Receptors
• Calcitonin Receptors
• Cannabinoid Receptor
• Chemokine Receptors
• Cholecystokinin Receptor
• Muscarinic Acetylcholine Receptor
• Coagulation Factor II Receptor
• Corticotropin-Releasing Hormone Receptor 1
• Dopamine Receptors
• Endothelin Receptor Type A
• GABAB Receptor
• Glucagon Receptor Family
• Metabotropic Glutamate Receptors
• Gonadotropin-Releasing Hormone Receptor
• Ghrelin Receptor
• Histamine Receptor
• Interleukin 8 Receptor
• Melanin-Concentrating Hormone Receptor 1
• Melanocortin Receptor
• Motilin Receptor
• Opiate Receptor-Like 1 and Opioid Receptors
• Oxytocin Receptor
• Prostaglandin Receptors
• GPCR44
• Purinergic P2Y Receptors
• Sphingosine-1-Phosphate Receptor 1
• Tachykinin Receptors
• Additional GPCR Modulators

Chapter 5

• DEALS, OBSERVATIONS, AND CONCLUSIONS
• 5.1. Selected GPCR-Related Deals
• 5.2. Strengths and Weaknesses of GPCRs as a Target Class
• Strengths
• Weaknesses
• 5.3. General Observations and Findings
• Diversity of GPCRs for Drug Discovery and Development
• Translation of Basic Research and New Technologies
• Functional Versus Ligand-Binding Screening Assays
  • * Cell Impedance Screening Technology
• Role of Allostery in Drug Discovery and Development
• Role of Dimers and Oligomers in Drug Discovery and Development
• Relationship of Signaling Pathway to Disease
• Deorphanization and Unfamiliar GPCRs
• Structure-Based Drug Design
• 5.4. Conclusions

Chapter 6

• EXPERT INTERVIEWS
• 6.1. Annette Gilchrist, PhD
• Adjunct Professor; Northwestern University
• 6.2. Graeme Milligan, PhD
• Professor of Molecular Pharmacology; Joint Research Director, Faculty of Biomedical and Life Sciences; University of Glasgow
• 6.3. Anonymous
• Screening and Profiling Director; Major Pharmaceutical Company X
• 6.4. P. Jeffrey Conn, PhD
• Lee E. Limbird Professor of Pharmacology; Director, Vanderbilt Program in Drug Discovery; Vanderbilt University Medical Center
• 6.5. Sidney Topiol, PhD
• Associate Director, Computational Chemistry; Lundbeck Research
• 6.6. Vincent Mutel, PhD
• CEO, Vice Chairman, and Co-Founder; Addex Pharmaceuticals

相關商品

Insight Pharma Reports發行的生物科技相關市場調查報告書

高含量分析:技術·用途·市場動態

High-Content Analysis: Technologies, Applications, and Market Dynamics

價格 : US $ 2495

出版日期 : 2011年12月

細胞因子治療及抑製劑：研發產品線、市場、策略性挑戰 - 概要

Cytokine-Based Therapies and Inhibitors: R&D Pipelines, Markets, and Strategic Issues - Overview

價格 : US $ 2495

出版日期 : 2011年09月

激酶標靶治療：開發產品線、挑戰及機會

Kinase-Targeted Therapeutics: Development Pipelines, Challenges, and Opportunities

價格 : US $ 3195

出版日期 : 2011年08月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!